WEI HU to Female
This is a "connection" page, showing publications WEI HU has written about Female.
Connection Strength
0.210
-
Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
Score: 0.014
-
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 2012 Sep; 13(11):1034-41.
Score: 0.012
-
Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9.
Score: 0.011
-
Update on aurora kinase inhibitors in gynecologic malignancies. Recent Pat Anticancer Drug Discov. 2008 Nov; 3(3):162-77.
Score: 0.009
-
Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res. 2005; 15(1):49-57.
Score: 0.007
-
Proteomics in cancer screening and management in gynecologic cancer. Curr Oncol Rep. 2004 Nov; 6(6):456-62.
Score: 0.007
-
Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics. 2003 Oct; 3(10):1904-11.
Score: 0.007
-
Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. Int J Gynecol Cancer. 2002 Mar-Apr; 12(2):202-7.
Score: 0.006
-
Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Anticancer Res. 2002 Mar-Apr; 22(2A):665-72.
Score: 0.006
-
Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res. 2000 Mar-Apr; 20(2A):729-33.
Score: 0.005
-
Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining. Cancer Epidemiol Biomarkers Prev. 1997 Sep; 6(9):711-8.
Score: 0.004
-
New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65.
Score: 0.004
-
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 2014 Dec 05; 7:109.
Score: 0.004
-
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48.
Score: 0.003
-
Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50.
Score: 0.003
-
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55.
Score: 0.003
-
Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
Score: 0.003
-
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95.
Score: 0.003
-
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200.
Score: 0.003
-
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.
Score: 0.003
-
Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.
Score: 0.003
-
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43.
Score: 0.003
-
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9.
Score: 0.003
-
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4.
Score: 0.003
-
Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res. 2012 Aug 01; 18(15):4114-21.
Score: 0.003
-
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8.
Score: 0.003
-
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9.
Score: 0.003
-
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer. 2010 Dec; 1(6):277-90.
Score: 0.003
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
Score: 0.003
-
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011 Jan; 120(1):113-20.
Score: 0.003
-
Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
Score: 0.003
-
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May; 120(5):1515-23.
Score: 0.003
-
Prognostic biomarkers in ovarian cancer. Cancer Biomark. 2010-2011; 8(4-5):231-51.
Score: 0.003
-
Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol. 2009 Oct; 201(4):367.e1-6.
Score: 0.002
-
Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients. Int J Gynecol Cancer. 2009 Feb; 19(2):178-85.
Score: 0.002
-
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009 Feb; 200(2):177.e1-9.
Score: 0.002
-
Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008 Sep; 110(3 Suppl 2):S67-71.
Score: 0.002
-
Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res. 2008 Oct; 25(10):2272-82.
Score: 0.002
-
Antisense-Snail transfer inhibits tumor metastasis by inducing E-cadherin expression. Anticancer Res. 2008 Mar-Apr; 28(2A):621-8.
Score: 0.002
-
Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):600-14.
Score: 0.002
-
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug; 106(2):375-80.
Score: 0.002
-
Hormonal therapy in ovarian cancer. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):325-38.
Score: 0.002
-
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug; 17(4):739-63.
Score: 0.002
-
Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol. 2007 Mar; 104(3):707-13.
Score: 0.002
-
Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1717-32.
Score: 0.002
-
Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006 Jun; 6(4):333-63.
Score: 0.002
-
Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets. 2006 Feb; 10(1):77-85.
Score: 0.002
-
Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial. Gynecol Oncol. 2005 Dec; 99(3 Suppl 1):S32-7.
Score: 0.002
-
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res. 2005 Jan 01; 11(1):113-22.
Score: 0.002
-
Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol. 2004 Jul; 130(7):423-8.
Score: 0.002
-
Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol. 2004 Apr; 93(1):149-54.
Score: 0.002
-
Dysregulation of the TGF-beta postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer. J Huazhong Univ Sci Technolog Med Sci. 2004; 24(1):62-5.
Score: 0.002
-
Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer. 2003 Nov-Dec; 13(6):701-34.
Score: 0.002
-
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol. 2004 Jan; 53(1):1-7.
Score: 0.002
-
Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003 Sep; 90(3):552-9.
Score: 0.002
-
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol. 2003 Oct; 129(10):549-55.
Score: 0.002
-
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res. 2003 Jul 15; 63(14):4174-80.
Score: 0.002
-
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003 Feb; 9(2):845-52.
Score: 0.002
-
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002 Sep; 16(9):1713-24.
Score: 0.002
-
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001 Nov 01; 92(9):2327-33.
Score: 0.001
-
Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial. Clin Cancer Res. 1998 Jun; 4(6):1383-91.
Score: 0.001
-
DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1997 Oct; 6(10):849-55.
Score: 0.001